LBL-066

LBL-066 is a preclinical-stage trispecific antibody being developed by Nanjing Leads Biolabs for the treatment of solid tumors. As a trispecific antibody, it is engineered to simultaneously bind to three distinct targets, a design typically intended to enhance tumor targeting specificity or to bridge immune cells with tumor cells to facilitate an anti-tumor response. LBL-066 is part of the company's Immuno-Oncology 2.0 (IO 2.0) pipeline, which focuses on next-generation biologics to overcome resistance to current immunotherapies. While its specific molecular targets have not been publicly disclosed, the drug is currently undergoing preclinical evaluation to support future clinical development.